artesunate
Selected indexed studies
- Artesunate Sensitizes human hepatocellular carcinoma to sorafenib via exacerbating AFAP1L2-SRC-FUNDC1 axis-dependent mitophagy. (Autophagy, 2024) [PMID:37733919]
- Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma. (Acta Pharmacol Sin, 2021) [PMID:32699265]
- Artesunate Inhibits the Cell Growth in Colorectal Cancer by Promoting ROS-Dependent Cell Senescence and Autophagy. (Cells, 2022) [PMID:36010550]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Artesunate Sensitizes human hepatocellular carcinoma to sorafenib via exacerbating AFAP1L2-SRC-FUNDC1 axis-dependent mitophagy. (2024) pubmed
- Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma. (2021) pubmed
- Artesunate Inhibits the Cell Growth in Colorectal Cancer by Promoting ROS-Dependent Cell Senescence and Autophagy. (2022) pubmed
- Artesunate: A review of its therapeutic insights in respiratory diseases. (2022) pubmed
- IV artesunate for severe malaria. (2020) pubmed
- Artesunate-multiple pharmacological effects beyond treating malaria. (2025) pubmed
- Artesunate targets cellular metabolism to regulate the Th17/Treg cell balance. (2023) pubmed
- Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria. (2022) pubmed
- Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria. (2019) pubmed
- Role of artesunate in autoimmune diseases and signaling pathways. (2023) pubmed